CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 620 enrolled
Drug / intervention
Erenumab 70 mg +2 moredrug
Likely dose
Erenumab 70 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03971071
NCT03971071Phase 4Completed
CompareCT.gov

A Phase 4, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Chronic Migraine and Medication Overuse Headache

Amgen·interventional·Posted Jun 3, 2019·Updated Sep 19, 2025

In Brief

A Phase 4 clinical trial evaluating Erenumab 70 mg, Erenumab 140 mg, and 1 other intervention for Migraine Headache. Completed, enrolled 620 participants across 94 sites in 12 countries.

Detailed Summary

Study 20170703 is a phase 4, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of erenumab against placebo in participants with chronic migraine (CM) who have a history of at least 1 preventive treatment failure and are diagnosed with medication overuse headache (MOH).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine Headache
CountriesAustralia, Austria, Czechia, Finland, France, Hungary, Italy, Poland, Portugal, Spain, United Kingdom, United States
Collaborators--

Timeline

Phase 4CompletedFinished
2020202120222023202420252026
First PostedJun 3, 2019
Enrollment StartOct 7, 2019
Primary CompletionDec 1, 2022
Study CompletionJun 13, 2023
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 7.1 years ago

Interventions

Erenumab 70 mgdrug

Erenumab once every 4 weeks. Subcutaneous injection.

Erenumab 140 mgdrug

Erenumab once every 4 weeks. Subcutaneous injection.

Placebodrug

Placebo once every 4 weeks. Subcutaneous injection.